What is AbbVie Inc. (ABBV)?

AbbVie Inc. (ABBV) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of ABBV?

The current price of ABBV is $288.38. Prices are updated in real time on Stocks360.

What is ABBV's price-to-earnings (PE) ratio?

ABBV's trailing twelve-month PE ratio is 81.24, based on current price and earnings per share data available on Stocks360.

What is ABBV's market capitalization?

ABBV's market capitalization is $509,592,447,062.00, placing it in the large-cap tier.

Does ABBV pay a dividend?

Yes. ABBV has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

AbbVie Inc. (ABBV)

Stock analysis · NYSE · Healthcare · Drug Manufacturers - General

$288.38

Market Cap

$509.59B

PE (TTM)

81.24

EPS (TTM)

N/A

Dividend Yield

2.40%

Beta

0.28

Day Range

$281.23 – $288.80

52-wk Range

$190.75 – $291.40

Avg Volume

N/A

Volume

579.52K

AbbVie Inc. (ABBV) is a publicly traded company in the Healthcare sector. Latest price: $288.38. Market cap $509.59B. Trailing PE 81.24. Dividend yield 2.40%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $227.54 2026-10-28 · $288.57 (+26.82%)

Earnings

Most Recent

Jul 31, 2026

EPS $3.65 vs est. $3.61

Beat by $0.04

Next Earnings

Oct 30, 2026

EPS estimate $3.73

Proprietary Signals

Signal snapshot temporarily unavailable.

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treat…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	81.24×
P/S (TTM)	7.91×
P/B	-86.05×
PEG	1.19×
P/FCF (TTM)	27.98×
EV / EBITDA	27.09×
EV / Sales	8.91×
Earnings Yield	1.24%
Free Cash Flow Yield	3.57%
Dividend Yield	2.40%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$573.85B
Revenue (TTM)	$64.39B
Net Income (TTM)	$6.30B
Free Cash Flow (TTM)	$20.33B
Net Debt	$64.25B
Working Capital	-$7.97B
Gross Margin	71.48%
Operating Margin	29.32%
Net Margin	9.81%
Return on Equity	-136.50%
Return on Invested Capital	13.46%